Managing impairment in patients with allergic rhinitis

Allergy and Asthma Proceedings

Volumn 27, Issue 1, 2006, Pages 12-16

  Stokes, Jeffrey ^a   Fenstad, Eric ^a   Casale, Thomas B ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; CAR DRIVING; CHILD; COGNITION; CONFERENCE PAPER; DRUG EFFECT; EDUCATIONAL STATUS; HAY FEVER; HUMAN; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; QUALITY OF LIFE;

ADULT; AUTOMOBILE DRIVING; CHILD; COGNITION; EDUCATIONAL STATUS; HISTAMINE H1 ANTAGONISTS; HUMANS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 33645125544     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Newacheck PW, and Stoddard JJ. Prevalence and impact of multiple childhood chronic illnesses. J Pediatr 124:40-48, 1994.
2. Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 90(suppl 3):7-12, 2003.
3. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20-year trends in the prevalence of asthma and hay fever in adults: The Midspan Family study surveys of parents and offspring. BMJ 321:88-92, 2000.
4. Woodwell DA, and Cherry DK. National ambulatory medical care survey: 2002 summary. Adv Data Vital Health Stat 346:1-44, 2004.
5. Sly RM. Epidemiology of allergic rhinitis. Clin Rev Allergy Immunol 22:67-103, 2002.
6. Bousquet J, Van Cauwenberge P, and Khaltaev N. ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl 5): S147-S336, 2001.
7. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm, managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 111:3835-5842, 2003.
8. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21:7-13, 2000.
9. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94:182-188, 1994.
10. Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma I: Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 149:371-375, 1994.
11. Meltzer EO, Nathan RA, Seiner JC, et al. Quality of life and rhinitis symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 99: S815-S819, 1997.
12. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114:S139-S145, 2004.
13. Marshall PS, and Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 71:251-258, 1993.
14. Marshall PS, O'Hara C, and Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 84:403-410, 2000.
15. Cuffel B, Wamboldt M, Borish L, et al. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics 40:491-496, 1999.
16. Reilly MC, Tanner A, and Meltzer EO. Work, classroom and activity impairment instruments; validation studies in allergic rhinitis. Clin Drug Invest 11:278-288, 1996.
17. Blanc P, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: Findings from a population-based study. J Clin Epidemiol 54:610-618, 2001.
18. Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 5(suppl):S235-S247, 1999.
19. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Allergy Immunol 104:364-369, 1999.
20. Juniper EF, Rohrbaugh T, and Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 111:484-490, 2003.
21. Juniper EF, Guyatt GH, and Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 93:413-423, 1994.
22. Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 101:163-170, 1998.
23. Arrighi HM, Cook CK, and Redding GJ. The prevalence and impact of allergic rhinitis among teenagers. J Allergy Clin Immunol 97:430, 1996.
24. Burres MP, Brâkenhielm G, and Irander K. How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol 78:29-34, 1997.
25. Simons FER. Advances in H1-Antihistamines. N Engl J Med 35:2203-2217, 2004.
26. Simons FE, and Simons KJ. H1 receptor antagonist treatment of chronic rhinitis. J Allergy Clin Immunol 81:975-980, 1988.
27. Okamura N, Yanai K, Higuchi M, et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 129:115-123, 2000.
28. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: Functional neuroimaging of histamine H1 receptors in human brain. Life Sci 72:409-414, 2002.
29. Tashiro M, Sakurado Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11c-doxepin positron emission tomography. J Clin Pharmacol 44:889-900, 2004.
30. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 287:337-344, 2002.
31. Richards S, Thornhill D, and Roberts H. How many people think they have hay fever and what they do about it. Br J Gen Pract 42:284-286, 1992.
32. Cockburn IM, Bailit HL, Berndt ER, et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 41:948-953, 1999.
33. Gilmore TM, Alexander BH, Mueller BA, et al. Occupational injuries and medication use. Am J Ind Med 30:234-239, 1996.
34. Finkle WD, Adams JL, Greenland S, et al. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 89:244-250, 2002.
35. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. Ann Intern Med 132:354-363, 2000.
36. Verster JC, and Volkerts ER. Antihistamines and driving ability: Evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 92:294-304, 2004.
37. Vuurman EFPM, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clini Pharmacor60:307-313, 2004.
38. Nicholson AN, Stone BM, Turner C, et al. Antihistamines and aircrew: Usefulness of fexofenadine. Aviat Space Environ Med 71:2-6, 2000.
39. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 71:121-126, 1993.
40. Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: A meta-analysis. J Allergy Clin Immunol 111: 770-776, 2003.
41. Shamsi Z, and Hindmarch I. Sedation and antihistamines: A review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 15(suppl 1):S3-S30, 2000.
42. Kay GG, Plotkin KE, Quig MB, et al. Sedating effects of AM/PM antihistamine dosing with evening chlorpheneramine and morning terfenadine. Am J Manag Care 3:1843-1848, 1997.